DC · State regulatory reference
District of Columbia.
Moderate
The District of Columbia follows a mainstream posture with no peptide/GLP-1-specific restrictions identified. Under DC Official Code § 3-1201.05 (Telehealth, added by D.C. Law 25-191, effective July 2024), a practitioner-patient relationship may be established through telehealth consistent with the standard of care, and Board of Medicine rules at 17 DCMR § 4618 permit real-time telemedicine to establish the relationship and evaluate the patient. Pharmacy compounding under 22-B DCMR and 17 DCMR Ch. 65 tracks federal 503A norms with no state-specific GLP-1/semaglutide rule found. No documented DC board enforcement against peptide/GLP-1 compounding or telehealth prescribing was located.
Last reviewed · 2026-05-25 · verified entry
Agencies
TPC notes
Telehealth
An initial visit and prescribing may occur via synchronous audio-video; DC Code § 3-1201.05 allows the practitioner-patient relationship to be established through telehealth per the standard of care, and 17 DCMR § 4618.3 lets physicians use real-time telemedicine to establish the relationship and evaluate the patient before prescribing (no blanket in-person exam mandate).
Compounding
DC pharmacy compounding is regulated under 22-B DCMR and 17 DCMR Ch. 65, generally following federal 503A standards; no distinctive DC USP addition or GLP-1/semaglutide-specific restriction was found in the accessible regulations.
Sources